Výsledky vyhledávání - "Sridharan, Nithya"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Effectiveness and tolerability of nimotuzumab in unresectable, locally advanced/metastatic esophageal cancer: Indian hospital-based retrospective evidence

Autor: Subramanian, Sundaram, Sridharan, Nithya, Balasundaram, V., Chaudhari, Sameer

Publikováno v: South Asian Journal of Cancer, Vol 8, Iss 2, Pp 112-115 (2019)
South Asian Journal of Cancer

Context: Epidermal growth factor receptor (EGFR) is overly expressed in esophageal squamous cell carcinoma (ESCC) and is important prognostic and predictive biomarker. Nimotuzumab is a humanized anti-EGFR monoclonal antibody and has documented promis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::881a5f0ee8a43e9b98114cac0fcff80e
http://journal.sajc.org/article.asp?issn=2278-330X

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Nimotuzumab with Induction Chemotherapy and Chemo-Radiation in Patients with Advanced Head and Neck Cancer

Autor: Sundaram Subramanium, Poojar Kiran, Sridharan Nithya, Venkatanarayan Balasundaram

Publikováno v: Journal of Cancer Therapy. :146-152

Background: Head and neck squamous cell carcinoma (HNSCC), is a common malignancy in the Indian Population. In locally advanced disease, chemoradiation is the standard of care. Although induction chemotherapy has been much studied, no clear benefit h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::349bc78e0bfb83e951bb2c099ac0256e
https://doi.org/10.4236/jct.2015.62016

Zobrazit plný text záznamu

Long term efficacy and safety of nimotuzumab in unresectable locally advanced squamous cell carcinoma of head and neck: A real world Indian experience

Autor: Sameer Chaudhari, Sundaram Subramanian, Sridharan Nithya

Publikováno v: Journal of Clinical Oncology. 36:e18077-e18077

e18077Background: Nimotuzumab is an anti-EGFR monoclonal antibody approved for the treatment of head and neck cancer (HNC) in India and 20 other countries. However, available evidence on long term ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::78d32caa7f78d10d8e576a6c607064c6
https://doi.org/10.1200/jco.2018.36.15_suppl.e18077

Zobrazit plný text záznamu

Tumour response and survival of treatment-naïve head and neck cancer patients treated with nimotuzumab: A systematic review and meta-analysis

Autor: Shyam Ji Rawat, Sridharan Nithya, Naresh Somani, Sundaram Subramanian, Sameer Chaudhari, Ashwani Marwah

Publikováno v: Journal of Clinical Oncology. 36:e18083-e18083

e18083Background: Several trials have studied the efficacy of Nimotuzumab in head and neck cancer. However, they are limited by small sample size and varying results. The purpose of this meta-analy...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7422f49f1761fe7728920e474c52123d
https://doi.org/10.1200/jco.2018.36.15_suppl.e18083

Zobrazit plný text záznamu

Akademický článek

Erratum: Evaluation of cytochrome P450 2C9 activity in normal, healthy, adult Western Indian population by both phenotyping and genotyping.

Publikováno v: Indian Journal of Pharmacology. Mar/Apr2017, Vol. 49 Issue 2, p213-213. 1p.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání